New Delhi [India], December 9 (ANI): AstraZeneca's Evusheld (Tixagevimab co-packaged with Cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected t